Drugs /

jdq443

Back to Drugs List

Overview

NCI Definition [1]:
An inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon administration, KRAS G12C inhibitor JDQ443 selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. KRAS, a member of the RAS family of oncogenes, serves an important role in cell signaling, division and differentiation. Mutations of KRAS may induce constitutive signal transduction leading to tumor cell growth, proliferation, invasion, and metastasis.

Clinical Trials

View Clinical Trials for jdq443

Jdq443 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating jdq443, 1 is phase 1/phase 2 (1 open).

KRAS G12C is the most frequent biomarker inclusion criterion for jdq443 clinical trials.

Malignant solid tumor is the most common disease being investigated in jdq443 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Jdq443
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating jdq443 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
kras g12c inhibitor jdq443, jdq 443, jdq-443
Drug Target(s) [2]:
KRAS
NCIT ID [1]:
C177916

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.